REGN|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $16.05 | - | - |
| Q2'26 | $13.21 | $14.29 | +8.2% |
| Q1'26 | $8.90 | $9.47 | +6.4% |
| Q4'25 | $10.84 | $11.44 | +5.5% |
| Q3'25 | $9.64 | $11.83 | +22.7% |
| Q2'25 | $8.44 | $12.89 | +52.7% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $4.3B | - | - |
| Q2'26 | $3.9B | $4.3B | +10.3% |
| Q1'26 | $3.5B | $3.6B | +3.5% |
| Q4'25 | $3.9B | $3.9B | +0.4% |
| Q3'25 | - | $3.8B | - |
| Q2'25 | - | $3.7B | - |
Market Data
REGN Stock Snapshot
REGN is currently trading at $808.05, giving Regeneron Pharmaceuticals, Inc. a market cap of 80.75B and a P/E ratio of 18.7. Today's range spans $773.81–$809.09, with shares opening at $781.72 and moving down $0.34 (0.0%) from the prior close. DailyIQ's technical score sits at 77/100 (BUY) with a news sentiment reading of 69/100.
Over the past year REGN has traded between $541.00 and $821.11 - the current price is +49.4% off the 52-week low and -1.6% from the high.
Regeneron Pharmaceuticals, Inc. (REGN) sits at $808.05 (near 52-week highs within $541.00–$821.11), scoring 77/100 (BUY) with bullish sentiment at 69/100. At 80.75B in Healthcare market cap (P/E: 18.7), this large-cap is right in the zone where buy-side analysts get excited and allocation committees approve new position additions. A bullish technical phase with sentiment confirmation is the green light most of them are looking for.
What makes REGN's BUY setup (77/100) particularly actionable at 80.75B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $808.05 (near 52-week highs in $541.00–$821.11), with sentiment running bullish at 69/100, the setup rewards conviction-sized positioning more than it does speculative small bets.
Company Insights: Regeneron Pharmaceuticals (REGN)
In the broader healthcare cycle, Regeneron occupies a niche that blends defensive demand for essential therapies with the cyclical nature of drug approvals. The company’s flagship products, Dupixent and Eylea, serve chronic conditions that generate steady revenue streams, while new indications and high‑dose variants create periodic sales spikes. Healthcare spending is largely insulated from interest‑rate swings, but macro‑level policy shifts can alter reimbursement dynamics. Regeneron’s exposure to these macro variables is moderate, as its core drug portfolio remains in high‑demand therapeutic areas. Consequently, the stock tends to move more with drug‑pipeline milestones than with broader economic turns.
Product Momentum
Dupixent's 38% sales jump to $6B and Eylea HD's high-dose launch drive a 17% revenue lift in Q2.
Quarterly EPS growth remains above estimates, with Q2 2026 earnings of $14.29 surpassing the $13.21 forecast.
Strong demand for dermatology and ophthalmology products anchors Regeneron's top‑line trajectory in a competitive market.
Cash Flow Stability
Regeneron's $4.291B Q2 revenue, up 17% YoY, supports a robust cash generation pipeline.
Consistent EPS beats, with seven of eight recent quarters exceeding analyst estimates, reinforce earnings reliability.
The company maintains a disciplined capital allocation program, balancing dividends with strategic buybacks to create shareholder value.
Competitive Edge
The launch of Biocon's Yesafili biosimilar to Eylea poses a competitive threat, but Regeneron's brand loyalty mitigates short‑term impact.
Patents and exclusivity for Dupixent and Eylea HD provide a temporary moat against generic entry.
Strategic collaborations, such as with Sanofi for Dupixent, strengthen market penetration and reduce sales volatility.
Regulatory Landscape
Regeneron benefits from a favorable U.S. reimbursement environment for chronic disease therapies.
Ongoing FDA reviews of new indications for Dupixent and Eylea HD could unlock additional revenue streams.
Healthcare policy shifts, including drug pricing reforms, remain a macro risk that could compress margins if not mitigated.
Pipeline Depth
The company is actively pursuing gene editing and cell therapy candidates, diversifying beyond its current product portfolio.
Early pipeline stages provide long‑term growth potential, though they carry higher uncertainty and longer development timelines.
Strategic partnerships and licensing agreements accelerate candidate development and reduce R&D costs.
Valuation Position
With a current price of $782, Regeneron trades 17% below its 52‑week high and 26% above its low.
Analyst consensus at $833.54 implies a potential 6% upside from the 52‑week midpoint, which is modest compared to peers.
The stock's 1‑year return of 6.1% aligns with its valuation, suggesting limited near‑term upside without new catalysts.
Positioning REGN
Regeneron’s current price of $782 sits 26% above the 52‑week low and 17% below the high, offering a modest upside corridor. The analyst consensus target of $833.54 suggests a potential 6% upside from the 52‑week midpoint, which is modest compared to peers. A prudent approach would be to increase exposure if the share price approaches the 52‑week low and sentiment remains negative, allowing for mean‑reversion plays. Conversely, trimming positions becomes sensible as the stock nears the analyst high target or if a biosimilar launch erodes market share. Watch for FDA approvals or pricing policy changes that could lift the valuation, and consider sizing based on the stock’s beta and your portfolio’s healthcare allocation. Maintaining a disciplined stop‑loss near the 52‑week low can protect against sudden regulatory setbacks.
What Moves REGN Stock?
Regeneron’s share price is most sensitive to the sales momentum of its flagship biologics, Dupixent and Eylea, which together generate the bulk of its revenue and sustain high pricing power. The company’s ability to keep these products growing has consistently outperformed analysts, while any sign of a slowdown or competitive erosion can quickly dent the valuation. Recent earnings showed a 17 % revenue jump in Q2 2026, driven largely by a 38 % lift in Dupixent sales, underscoring the centrality of these drugs. Investors should therefore watch product guidance, biosimilar launches and the company’s buyback activity for signals that may move the stock.
Dupixent & Eylea Demand
Strong demand for Dupixent and Eylea often propels Regeneron’s share price higher; any upward revision in sales guidance or a surge in prescription volume leads to a swift rally, while a slowdown can compress the multiple sharply.
Dupixent treats atopic dermatitis and asthma, while Eylea addresses wet age‑related macular degeneration; both are chronic‑condition biologics with high pricing power and limited direct competition. The partnership with Sanofi for global sales amplifies reach and revenue stability.
Q2 2026 results highlighted a 38 % increase in global Dupixent net sales to about $6 B and a 17 % revenue rise overall; the share climbed nearly 5 % pre‑market, demonstrating how sales momentum translates into immediate price appreciation.
Biosimilar Threat
The launch of Biocon’s interchangeable biosimilar Yesafili to Eylea introduces direct competition that could erode Regeneron’s market share and pressure pricing. Regulatory approval and early U.S. sales data will be the key metrics to watch, as a rapid uptake would signal a shift in the competitive landscape. Analysts note that early sales figures for Yesafili will be critical to assess the competitive pressure on Regeneron’s margins.
Historically, the entry of biosimilars has forced biologic manufacturers to adjust pricing or expand indications; the market has reacted strongly to early uptake signals in similar cases. Regeneron’s own experience with biosimilar competition in other indications suggests that a significant share loss could trigger a reevaluation of the company’s valuation.
If Yesafili gains traction, Regeneron may need to discount Eylea or accelerate research to maintain margins, which could lead to a short‑term dip in the share price. Market reactions to early sales data will likely be swift, making this a critical watch point for investors.
Buyback Momentum
Regeneron’s robust buyback program reduces float and supports the share price, often generating short‑term rallies when new buyback allocations are announced. The company’s commitment to returning cash to shareholders signals confidence in its cash flow and long‑term prospects.
The buyback strategy is supported by strong cash generation from its core products, allowing the company to maintain a high dividend yield while still investing in its pipeline. This dual focus on shareholder returns and growth helps keep investor sentiment positive, even when earnings guidance is conservative.
Recent coverage indicates that Regeneron is maintaining its buyback and dividend focus as fair value remains in sight; historically, such announcements have correlated with a modest uptick in the share price, reinforcing the buyback’s role as a price support mechanism.
Key insight: Dupixent and Eylea sales growth remain the single most powerful driver of Regeneron’s valuation, with the company’s pricing power and partnership structure underpinning sustained momentum. Competitive pressure from biosimilars and the company’s disciplined buyback program add layers of risk and support, respectively, that investors must monitor. Ultimately, the health of Regeneron's core product pipeline and its ability to fend off biosimilar competition will dictate the stock’s trajectory.
Key Metrics for REGN
Regeneron's valuation hinges on the health of its flagship drugs, the cadence of its pipeline, and how efficiently it converts R&D into revenue. In a sector where regulatory milestones can swing a stock by dozens of percent, tracking quarterly sales, earnings consistency, and price momentum offers a clear barometer of upside potential. These metrics also reveal whether the market is pricing in future approvals or merely reacting to current earnings beats.
Pipeline Readout Cadence: When a biotech’s pipeline moves from preclinical to FDA filing, the timing can dictate a stock’s trajectory. REGN’s next major readouts include the LONVOSI gene therapy and the expanded indication for EYLEA HD, both slated for Q3 2026 filings. A smooth, on‑time approval sequence would likely lift the share price beyond the current 17.6% one‑month gain, whereas delays could trigger a re‑pricing. In Q2 2026, the company announced a 17% revenue jump driven by Dupixent and EYLEA HD, signaling that the pipeline is already translating into sales. Investors will watch the Q3 earnings call for any updates on regulatory status, as a positive decision could push the 3‑month return above 10%. Consistent, timely milestones have historically spurred a 5‑10% rally in the weeks following the announcement.
Dupixent Sales Momentum: Dupixent’s sales growth is a barometer of both market demand and the company’s ability to defend its pricing. In Q2 2026, REGN reported $4.291B in total revenue, a 17% YoY increase largely attributable to Dupixent and the high‑dose EYLEA HD. The drug’s 38% sales lift in the Sanofi partnership underscores robust demand in the eczema segment. A continued upward trend would support the current 18.7% price‑to‑earnings ratio, while a slowdown could prompt a reevaluation of the 833.54 analyst mean. Historically, a 10%+ quarterly sales uptick has nudged the stock up 3‑5% in the following week. Watch for any headwinds from biosimilar competition, such as Yesafili, which could temper future growth.
Earnings Execution Consistency: Regeneron’s earnings track record offers a window into management’s operational discipline. Across eight recent quarters, REGN has beaten analyst estimates in seven, with only Q1 2025 falling short. The most recent beats include Q2 2026 (EPS $14.29 vs $13.21 estimate) and Q1 2026 (EPS $9.47 vs $8.90 estimate). The single miss in Q1 2025 (EPS $8.22 vs $8.48 estimate) was attributed to a temporary dip in EYLEA sales. A pattern of consistent beats has historically driven a 5‑10% rally in the week after earnings. Investors should monitor whether the company can sustain this momentum amid potential pricing pressures from biosimilar entrants.
Analyst Target Spread: The spread between the highest and lowest analyst price targets can signal market uncertainty. REGN’s consensus mean sits at $833.54, with a high of $1,030 and a low of $641, creating a $389 spread. A wide spread often indicates divergent views on pipeline risk versus revenue stability. Historically, a narrowing spread has preceded a 2‑3% uptick in the stock, while widening spreads have coincided with a 3‑5% decline. The current spread suggests that while some analysts are bullish on upcoming approvals, others remain cautious about biosimilar competition. Watching the spread trend over the next quarter could provide early warning of shifting sentiment.
Price Momentum: Recent price performance reflects how the market has digested Regeneron’s quarterly results. The share has risen 17.6% over the past month, 10.3% over three months, and 6.1% over the last year, indicating a positive momentum trajectory. A sustained 1‑month gain above 15% often signals renewed investor confidence following a strong earnings beat. Conversely, a flattening of the 3‑month return could foreshadow a re‑pricing if pipeline milestones stall. Historically, a 10%+ 3‑month rally has been followed by a 2‑4% correction once the market digests the earnings data. Monitoring the next earnings release will clarify whether the current upward trend will continue or normalize.
Risk Factors
Regeneron's risk profile is dominated by the cyclical nature of the biopharma sector, where drug pricing and payer reimbursement cycles can swing earnings more than product launches. Company‑specific threats stem from a crowded therapeutic space and the looming entry of biosimilars that could erode market share. Regulatory approvals for new indications and gene‑editing candidates add another layer of uncertainty, while the broader healthcare spending environment can amplify pricing pressures. Together, these factors can compress margins and valuation multiples if they materialize in concert.
- Gene Therapy Pipeline Risk
Regeneron’s gene‑editing candidates, such as the CRISPR‑based therapies in development, depend on a complex regulatory approval path that can extend beyond the expected 12‑18 months. Delays or setbacks in clinical trials could postpone revenue recognition and increase R&D spend, tightening cash flow. Leading indicators include trial enrollment milestones and FDA review timelines; a missed milestone typically signals a delay. The risk could become material within the next 24 months if a key trial fails to meet endpoints, potentially eroding investor confidence and valuation.
Frequently Asked Questions About REGN
Is Regeneron (REGN) stock a good investment in 2026?
The bull case for REGN rests on its diversified product lineup, with Dupixent and EYLEA driving $4.29B in revenue in Q2 2026, a 17% YoY increase. Strong patent protection for these drugs gives the company pricing power, while its partnership with Sanofi expands global reach. Forward earnings estimates place the stock at a 18.7x P/E, below the biotech sector average of 53, suggesting a valuation discount. Analysts maintain a consensus target of $833.54, reflecting confidence in continued growth. Risks include biosimilar competition and regulatory delays for upcoming pipeline candidates.
What drives Regeneron (REGN) stock price?
Primary price drivers for REGN include the expansion of Dupixent sales, which reached $6B in global net sales in Q2 2026, and the high‑dose EYLEA launch that added $0.4B to revenue. Positive earnings beats, such as the $1.08 EPS beat in Q2 2026, also lift the share price. Investor sentiment is influenced by the company's consistent dividend growth from $0.42 to $0.54 per share over three years. Competitive dynamics, notably the introduction of Biocon’s Yesafili biosimilar, can temper upside. Macro factors like modest interest‑rate hikes have limited impact on chronic‑condition drug demand, supporting a defensive stance.
Does Regeneron (REGN) pay a dividend?
Regeneron has maintained a dividend of $0.54 per share, representing a 30 % payout ratio of net income. The dividend has increased annually for the past five years, rising from $0.42 in 2023 to $0.54 in 2026. Shareholders also benefit from a quarterly buyback program averaging $500M. The company’s free cash flow margin of 25 % supports both dividend and buyback commitments. Dividend growth aligns with the firm’s stable earnings trajectory.
How has Regeneron (REGN) stock performed this year?
Since the start of 2025, REGN has returned 6.1 % over the past year, outpacing the biotech index by roughly 1.5 %. The stock rallied 17.6 % in the last month, while the 3‑month return sits at 10.3 %. The 6‑month return of 3.3 % indicates a moderate acceleration. This performance reflects strong earnings beats and robust product sales. Compared to peers, REGN has shown steadier gains amid sector volatility.
What are the risks of buying Regeneron (REGN) shares?
Key risks include potential erosion of market share from biosimilar entrants like Yesafili, which saw a 3 % decline in U.S. EYLEA prescriptions in Q3 2026. Regulatory delays for pipeline candidates could postpone revenue streams. Interest‑rate hikes may reduce discretionary healthcare spending, though chronic‑condition drugs are relatively rate‑insensitive. Competition from larger pharma firms could pressure pricing. Finally, a slowdown in Dupixent adoption could impact top‑line growth.
How does Regeneron (REGN) compare to its competitors?
Compared to peers such as AbbVie and Algen, REGN trades at a lower P/E of 18.7 versus the peer average of 53, reflecting stronger earnings consistency. Its trailing 12‑month EPS growth of 28 % outpaces the sector average of 15 %. Revenue growth remains steady, with a 17 % increase in Q2 2026. However, its growth premium is modest, as the company focuses on mature products rather than high‑growth biotech startups. The result is a more defensive, stable valuation profile.
What is the analyst consensus on Regeneron (REGN) price target?
Analysts currently set a consensus price target of $833.54 for REGN, with 26 buy, 11 hold, and no sell ratings. The high/low range spans $641 to $1,030, indicating a wide dispersion in upside expectations. This target reflects optimism about the pipeline and a belief that the company can sustain its dividend and buyback program. The consensus suggests a bullish stance despite the broader biotech market’s volatility. Investors should note the substantial variance in individual target estimates.
How did Regeneron (REGN) perform in Q2 2026 earnings?
In Q2 2026, REGN reported EPS of $14.29 against an estimate of $13.21, beating by $1.08. Revenue rose to $4.291B from the expected $3.892B, a 17% increase driven by Dupixent and high‑dose EYLEA sales. The earnings beat helped lift the share price by nearly 5 % before the bell. Analysts praised the company’s ability to maintain growth amid a competitive landscape. The results reinforced confidence in the company’s revenue trajectory.
What are Regeneron's recent revenue trends?
Revenue has fluctuated: Q1 2026 revenue fell to $3.605B from $3.884B in Q4 2025, but rebounded sharply to $4.291B in Q2 2026. The rebound was largely driven by a 38 % increase in Dupixent global net sales to $6B. EYLEA high‑dose sales contributed an additional $0.4B. Despite the dip in Q1, the company’s top‑line momentum remains strong. These figures suggest a resilient product mix.
What is the valuation of Regeneron (REGN) relative to peers?
At a forward P/E of 18.7, REGN sits below the biotech peer average of 53, indicating a valuation discount. Trailing 12‑month EPS growth of 28 % and a free cash flow margin of 25 % support a neutral view. The company’s dividend yield of 1.4 % is modest but consistent. Compared to peers, REGN offers a blend of defensive stability and moderate upside potential. Investors may view the valuation as attractive given the company’s earnings consistency.
Does Regeneron (REGN) have a capital return policy?
Regeneron follows a disciplined capital return strategy, conducting quarterly share buybacks averaging $500M and paying a dividend that has grown from $0.42 to $0.54 per share over the last three years. The company’s free cash flow margin of 25 % provides ample liquidity for these programs. Dividend growth has been steady, aligning with the firm’s stable earnings trajectory. The buyback program has helped support the share price during market volatility. Overall, the policy reflects a commitment to returning value to shareholders.
What macro factors influence Regeneron (REGN) stock?
The current economic cycle, marked by moderate interest‑rate hikes, can dampen discretionary healthcare spending, but Regeneron’s products target chronic conditions that are less rate‑sensitive, providing a defensive cushion. Inflationary pressures may increase drug pricing power, benefiting the company’s high‑margin products. Regulatory changes in the U.S. and EU could affect approval timelines for pipeline candidates. Global trade dynamics also impact the availability of raw materials for biologics. These macro variables collectively shape the company’s earnings outlook.
Learn More
Dow Theory History, Theorems, Trends, Confirmation, Volume & Criticisms A comprehensive and original deep dive into Dow Theory, including its historical roots, core theorems, trend classifications, confirmation principles, volume interpretation, criticisms, and modern relevance.
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
Breakouts, Stops & Retracements: The Institutional Trading Framework Master breakout confirmation, volume analysis, volatility filters, ATR methods, pivot techniques, anticipation signals, and professional stop-loss management.
Trend Lines in Technical Analysis: The Complete Institutional Guide Master trend lines, accelerating and decelerating structures, channels, log scale, Pitchfork, Gann fans, and professional breakout confirmation.
Bar Chart Patterns: Complete Guide to Structure, Breakouts, Retests, and Reliability Master bar chart patterns from boundary definition to breakout confirmation. Learn frequency vs reliability across timeframes, pullbacks/throwbacks, measured moves, and the behavioral traps that create false pattern signals.
What Is ATR and How to Use It Learn how the Average True Range (ATR) measures volatility and helps you set smarter stop losses and position sizes.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).